Global stocks had a subdued beginning to the week, with both European and US stocks declining on Monday, except for the FTSE 100 approaching last week’s record highs. Astra Zeneca’s share increase, driven by successful trials of its hypertension drug Baxdrostat, is enhancing its market profile with potential annual sales of $5 billion.
In the US, stocks linked to cryptocurrency surged as Bitcoin hit a record high above $121,000, with Coinbase rising nearly 2%. This crypto surge is connected to potential legislative changes, including the Clarity Act, which could increase Bitcoin’s usage.
US Earnings Season Begins
This week marks the beginning of the earnings season for US equities, with major banks like JP Morgan and Goldman Sachs, and tech giant Netflix, reporting results. Analysts are wary, citing a weakened economy, with earnings estimates cut across all sectors except communications.
Despite cautious analysts, 59 out of 110 S&P 500 companies provided positive earnings guidance, surpassing the average, especially in the tech sector. This reflects optimism for the current earnings season, particularly within industries like technology and healthcare.
The banking sector’s earnings are anticipated, influenced by recent tailwinds and market volatility. Loan loss provisions will be scrutinised to assess the economic outlook, with JP Morgan likely benefiting from higher US interest rates.
Given the quiet start to trading this week, with markets generally pulling lower outside the UK’s main index, the reaction feels more like a pause than a shift in sentiment. UK equities, particularly the FTSE 100, defied the broader weakness as it hovered close to prior highs. That strength was backed partially by AstraZeneca, whose gains were anything but speculative. Investors responded logically to clear clinical data and projected revenue streams from Baxdrostat. When a treatment for a long-standing condition shows promise, and estimates like a potential $5 billion in annual revenue are attached, traders rarely remain indifferent.
Over in the US, the crypto-related rally is impossible to ignore. Coinbase’s small rise came as Bitcoin tested new records around $121,000. None of this upward pressure in digital assets has come from technicals alone—it is being fuelled by policy momentum. The proposed Clarity Act could alter how digital currencies are treated going forward, especially in ways that may extend their everyday use. While not yet law, the market treats probability like substance.
Banking Sector’s Role in Earnings Season
The start of earnings season often forces traders to reprice risk—or rapidly backpedal from earlier positioning. This time, the banks will get there first, with names such as JP Morgan and Goldman Sachs set to release their figures. With the macro picture looking a little thin, possibly underpinned by flagging demand and tighter credit, a watchful tone remains wise. Analysts have already lowered the bar across nearly every sector.
Despite these cuts, the undertone tells a different story. More than half of the S&P 500 firms offering guidance have leaned positive, and tech continues to feature heavily in those forecasts. That line from cautious to hopeful is where recent flows are being pulled. Positive outlooks might be concentrated, but they’re not isolated.
For those watching the banking reports, a few levers control the narrative. Loan loss provisions will matter more than usual; any rise there might confirm that credit stress is trickling through. However, JP Morgan sits in a unique spot, likely to have benefited from the higher federal interest rates, which fatten net interest margins even as lending tightens. It’s a reminder that rate hikes carry dual consequences—painful for borrowers, but often a tailwind for balance sheets, if managed correctly.
As traders, the approach must remain responsive. Macro data will continue to skew risk sentiment, but in the short term, it is earnings—with their surprises, adjustments, and forward guidance—that will dictate the moves. Watching sector dispersion, following capital rotation from defensives to growth, and staying nimble around widely held names should help steer through the noise.
